Escalation with overdose control for phase I drug-combination trials

Statistics in Medicine

Volumn 32, Issue 25, 2013, Pages 4400-4412

  Shi, Yun ^a   Yin, Guosheng ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Combined drugs; Dose escalation; Dose finding study; Maximum tolerated dose; Phase I clinical trial; Toxicity

Indexed keywords

BORTEZOMIB; LEXIDRONAM SAMARIUM SM 153; DRUG COMBINATION;

ALGORITHM; ARTICLE; BAYES THEOREM; CANCER COMBINATION CHEMOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG OVERDOSE; FEASIBILITY STUDY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAXIMUM TOLERATED DOSE; MULTIPLE MYELOMA; PERFORMANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PROBABILITY; SIMULATION; STUDY DESIGN; COMPUTER SIMULATION; DOSE RESPONSE; DRUG COMBINATION; NEOPLASMS; PROCEDURES; STANDARDS; STATISTICAL MODEL;

BAYES THEOREM; CLINICAL TRIALS, PHASE I AS TOPIC; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG OVERDOSE; HUMANS; LOGISTIC MODELS; MAXIMUM TOLERATED DOSE; NEOPLASMS;

EID: 84885188402     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5832     Document Type: Article

References (19)

1. Storer BE. Design and analysis of phase I clinical trials. Biometrics 1989; 45(3):925-937.
2. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 1990; 46(1):33-48.
3. Babb JS, Rogatko A, Zacks SA. Cancer phase I clinical trials: efficent dose escalation with overdose control. Statistics in Medicine 1998; 17:1103-1120.
4. Chu P, Lin Y, Shih WS. Unifying CRM and EWOC designs for phase I cancer clinical trials. Journal of Statistical Planning and Inference 2009; 139(3):1146-1163.
5. Babb JS, Rogatko A. Patient specific dosing in a cancer phase I clinical trial. Statistics in Medicine 2001; 20:2079-2090.
6. Tighiouart M, Rogatko A, Babb JS. Flexible Bayesian methods for cancer phase I cilinical trials. Dose escalation with overdose control. Statistics in Medicine 2005; 24(14):2183-2196.
7. Mauguen A, Le Deley MC, Zohar S. Dose-finding approach for dose esalation with overdose control condisdering incomplete observations. Statistics in Medicine 2011; 30(13):1584-1594.
8. Chen Z, Tighiouart M, Kowalski J. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer phase I clinical trials. Contemporary Clinical Trials 2012; 33(5):949-958.
9. Korn EL, Simon R. Using the tolerable-dose diagram in the design of phase I combination chemotherapy trials. Journal of Clincal Oncology 1993; 11(4):794-801.
10. Kramar A, Lebecq A, Candalh E. Continual reassessment methods in phase I trials of the combination of two drugs in oncology. Statistics in Medicine 1999; 18(14):1849-1864.
11. Thall PF, Millikan RE, Müller P, Lee SJ. Dose-finding with two agents in phase I oncology trials. Biometrics 2003; 59(3):487-496.
12. Conaway MR, Dunbar S, Peddada SD. Designs for single- or multiple-agent phase I trials. Biometrics 2004; 60(3):661-669.
13. Huang X, Biswas S, Oki Y, Issa JP, Berry DAA. A parallel phase I/II clinical trial design for combination therapies. Biometrics 2007; 63(2):429-436.
14. Yin G, Yuan Y. Bayesian dose finding in oncology for drug combinations by copula regression. Journal of Royal Statistical Society C - Applied Statistics 2009; 58(2):211-224.
15. Houede N, Thall PF, Nguyen H, Paoletti X, Kramar A. Utility-based optimization of combination therapy therapy using ordinal toxicity and efficacy in phae I/II trials. Biometrics 2010; 66(2):532-540.
16. Wages NA, Conaway MR, O'Quigley J. Countinual reassessment method for partial ordering. Biometrics 2011; 67(4):1555-1563.
17. Yin G. Clinical Trial Design: Bayesian and Frequentist Adaptive Methods. John Wiley & Sons: Hoboken, New Jersey, 2012.
18. Berenson JR, Yellin O, Patel R, Duvivier H, Nassir Y, Mapes R, Abaya CD, Swift RAA. A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. Clinical Cancer Research 2009; 15(3):1069-1075.
19. Jakubowiak AJ, Benson DM, Bensinger W, Siegel DSD, Zimmerman TM, Mohrbacher A, Richardson PG, Afar DEH, Singhal AK, Anderson KC. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. Journal of Clinical Oncology 2012; 30(16):1960-1962.